Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? – A Case Report

References

• Tobón GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. J Autoimmun. 2010;35:10–14. doi:10.1016/j.jaut.2009.12.009
   PubMed Web of Science ®Google Scholar
• Albers HM, Wessels JAM, Van Der Straaten RJHM, et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Care Res. 2009;61:46–51. doi:10.1002/art.24087
   Web of Science ®Google Scholar
• Bedoui Y, Guillot X, Sélambarom J, et al. Methotrexate an old drug with new tricks. Int J Mol Sci. 2019;20:5023. doi:10.3390/ijms20205023
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr., et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26. doi:10.1002/art.39480
   PubMed Web of Science ®Google Scholar
• Jenko B, Tomšič M, Jekić B, Milić V, Dolžan V, Praprotnik S. Clinical pharmacogenetic models of treatment response to methotrexate monotherapy in Slovenian and Serbian rheumatoid arthritis patients: differences in patient’s management may preclude generalization of the models. Front Pharmacol. 2018;9. doi:10.3389/fphar.2018.00020
   PubMed Web of Science ®Google Scholar
• Mikkelsen TS, Thorn CF, Yang JJ, et al. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics. 2011;21:679–686. doi:10.1097/FPC.0b013e328343dd93
   PubMed Web of Science ®Google Scholar
• Eektimmerman F, Swen JJ, Madhar MB, Allaart CF, Guchelaar H-J. Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review. Pharmacogenomics J. 2020;20:159–168. doi:10.1038/s41397-019-0098-9
   PubMed Web of Science ®Google Scholar
• Malik F, Ranganathan P. Methotrexate pharmacogenetics in rheumatoid arthritis: a status report. Pharmacogenomics. 2013;14:305–314. doi:10.2217/pgs.12.214
   PubMed Web of Science ®Google Scholar
• Jeiziner C, Suter K, Wernli U, et al. Pharmacogenetic information in Swiss drug labels - a systematic analysis. Pharmacogenomics J. 2021;21:423–434. doi:10.1038/s41397-020-00195-4
   PubMed Web of Science ®Google Scholar
• Lima A, Bernardes M, Azevedo R, et al. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci. 2014;142:196–209. doi:10.1093/toxsci/kfu162
   PubMed Web of Science ®Google Scholar
• Chango A, Emery-Fillon N, de Courcy GP, et al. A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab. 2000;70:310–315. doi:10.1006/mgme.2000.3034
   PubMed Web of Science ®Google Scholar
• Samara SA, Irshaid YM, Mustafa KN. Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients. Int J Clin Pharmacol Ther. 2014;52:746–755. doi:10.5414/CP202098
   PubMed Web of Science ®Google Scholar
• Swierkot J, Slezak R, Karpinski P, et al. Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR, TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis. Pol Arch Med Wewn. 2015;125:152–161. doi:10.20452/pamw.2707
   PubMed Web of Science ®Google Scholar
• Dervieux T, Kremer J, Lein DO, et al. Contribution of common polymorphisms in reduced folate carrier and γ-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics. 2004;14:733–739. doi:10.1097/00008571-200411000-00004
   PubMedGoogle Scholar
• de Graaf D, Sharma RC, Mechetner EB, Schimke RT, Roninson IB. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci U S A. 1996;93:1238–1242. doi:10.1073/pnas.93.3.1238
   PubMed Web of Science ®Google Scholar
• Kusuhara H, Sugiyama Y. ATP-binding cassette, subfamily G (ABCG family). Pflugers Arch. 2007;453:735–744. doi:10.1007/s00424-006-0134-x
   PubMed Web of Science ®Google Scholar
• Muto S, Minamitani N, Ogura T, et al. Good response to methotrexate is associated with a decrease in the gene expression of ABCG2, a drug transporter, in patients with rheumatoid arthritis. Mod Rheumatol. 2021;31:1079–1086. doi:10.1080/14397595.2021.1879429
   PubMed Web of Science ®Google Scholar
• Esmaili MA, Kazemi A, Faranoush M, et al. Polymorphisms within methotrexate pathway genes: relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia. Iran J Basic Med Sci. 2020;23:800–809. doi:10.22038/ijbms.2020.41754.9858
   PubMed Web of Science ®Google Scholar
• Jenko B, Lusa L, Tomsic M, Praprotnik S, Dolzan V. Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. Pharmacogenomics J. 2017;17:412–418. doi:10.1038/tpj.2016.36
   PubMed Web of Science ®Google Scholar
• Muralidharan N, Antony PT, Jain VK, Mariaselvam CM, Negi VS. Multidrug resistance 1 (MDR1) 3435C>T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis. Eur J Clin Pharmacol. 2015;71:959–965. doi:10.1007/s00228-015-1885-0
   PubMed Web of Science ®Google Scholar
• Takatori R, Takahashi KA, Tokunaga D, et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol. 2006;24:546–554.
   PubMed Web of Science ®Google Scholar
• Kato T, Hamada A, Mori S, Saito H. Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet. 2012;27:192–199. doi:10.2133/dmpk.DMPK-11-RG-066
   PubMed Web of Science ®Google Scholar
• Plaza-Plaza JC, Aguilera M, Cañadas-Garre M, et al. Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis. OMICS J Integr Biol. 2012;16:589–595. doi:10.1089/omi.2011.0142
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Culverhouse R, Marsh S, et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in caucasian and African American patients with rheumatoid arthritis. J Rheumatol. 2008;35:572–579.
   PubMed Web of Science ®Google Scholar
• Zajc Avramovic M, Dolzan V, Toplak N, Accetto M, Lusa L, Avcin T. Relationship between polymorphisms in methotrexate pathway genes and outcome of methotrexate treatment in a cohort of 119 patients with juvenile idiopathic arthritis. J Rheumatol. 2017;44:1216–1223. doi:10.3899/jrheum.160950
   PubMed Web of Science ®Google Scholar
• van de Steeg E, van der Kruijssen CM, Wagenaar E, et al. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos. 2009;37:277–281. doi:10.1124/dmd.108.024315
   PubMed Web of Science ®Google Scholar
• Meyer Zu Schwabedissen HE, Kim RB. Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms. Mol Pharm. 2009;6:1644–1661. doi:10.1021/mp9000298
   PubMed Web of Science ®Google Scholar
• Hayashi H, Fujimaki C, Daimon T, Tsuboi S, Matsuyama T, Itoh K. Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J Clin Pharm Ther. 2009;34:355–361. doi:10.1111/j.1365-2710.2009.01046.x
   PubMed Web of Science ®Google Scholar
• Haagsma CJ, Blom HJ, Van Riel PLCM, et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis. 1999;58:79–84. doi:10.1136/ard.58.2.79
   PubMed Web of Science ®Google Scholar
• Kim SK, Jun JB, El-Sohemy A, Bae SC. Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate. J Rheumatol. 2006;33:1266–1274.
   PubMed Web of Science ®Google Scholar
• Weisman MH, Furst DE, Park GS, et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum. 2006;54:607–612. doi:10.1002/art.21573
   PubMed Web of Science ®Google Scholar
• Dervieux T, Wessels JAM, Van Der Straaten T, et al. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet Genomics. 2009;19:935–944. doi:10.1097/FPC.0b013e32833315d1
   PubMed Web of Science ®Google Scholar
• Mena JP, Salazar-Páramo M, González-López L, et al. Polymorphisms C677T and A1298C in the MTHFR gene in Mexican patients with rheumatoid arthritis treated with methotrexate: implication with elevation of transaminases. Pharmacogenomics J. 2011;11:287–291. doi:10.1038/tpj.2010.32
   PubMed Web of Science ®Google Scholar
• Wessels JA, de Vries-bouwstra JK, Heijmans BT, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 2006;54:1087–1095. doi:10.1002/art.21726
   PubMed Web of Science ®Google Scholar
• Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658–666. doi:10.1002/art.24516
   PubMed Web of Science ®Google Scholar
• Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum. 2006;54:1366–1377. doi:10.1002/art.21762
   PubMed Web of Science ®Google Scholar
• Wessels JAM, Kooloos WM, De Jonge R, et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2006;54:2830–2839. doi:10.1002/art.22032
   PubMed Web of Science ®Google Scholar
• Kishi S, Cheng C, French D, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007;109:4151–4157. doi:10.1182/blood-2006-10-054528
   PubMed Web of Science ®Google Scholar
• Imanishi H, Okamura N, Yagi M, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet. 2007;52:166–171. doi:10.1007/s10038-006-0096-z
   PubMed Web of Science ®Google Scholar
• ICH topic E15: definitions of genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data, sample coding categories; 2007. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-15-definitions-genomic-biomarkers-pharmacogenomics-pharmacogenetics-genomic-data-sample-coding_en.pdf. Accessed July 10, 2019.
   Google Scholar
• Jekic B, Maksimovic N, Damnjanovic T. Methotrexate pharmacogenetics in the treatment of rheumatoid arthritis. Pharmacogenomics. 2019;20:1235–1245. doi:10.2217/pgs-2019-0121
   PubMed Web of Science ®Google Scholar
• Fiehn C, Holle J, Iking-Konert C, et al. S2e-Leitlinie: therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten. Z Fur Rheumatol. 2018;77:35–53. doi:10.1007/s00393-018-0481-y
   PubMed Web of Science ®Google Scholar
• Drozdzik M, Rudas T, Pawlik A, Gornik W, Kurzawski M, Herczynska M. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J. 2007;7:404–407. doi:10.1038/sj.tpj.6500438
   PubMed Web of Science ®Google Scholar
• Clinical annotation for s1045642 (ABCB1) and methotrexate; 2021. Available from: https://www.pharmgkb.org/clinicalAnnotation/655385462. Accessed October 01, 2021.
   Google Scholar
• Machaj F, Rosik J, Szostak B, Pawlik A. The evolution in our understanding of the genetics of rheumatoid arthritis and the impact on novel drug discovery. Expert Opin Drug Discov. 2020;15:85–99. doi:10.1080/17460441.2020.1682992
   PubMed Web of Science ®Google Scholar
• Zanger UM, Klein K, Thomas M, et al. Genetics, epigenetics, and regulation of drug-metabolizing cytochrome P450 enzymes. Clin Pharmacol Ther. 2014;95:258–261. doi:10.1038/clpt.2013.220
   PubMed Web of Science ®Google Scholar
• Stamp LK, Chapman PT, O’Donnell JL, et al. Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenet Genomics. 2010;20:367–376. doi:10.1097/FPC.0b013e3283398a71
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith RL, Campalani E, et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol. 2008;128:1925–1929. doi:10.1038/jid.2008.16
   PubMed Web of Science ®Google Scholar
• Dervieux T, Furst D, Lein DO, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004;50:2766–2774. doi:10.1002/art.20460
   PubMed Web of Science ®Google Scholar